AbGenomics raises $9.6 mn for advancing its therapeutic antibodies for … – pharmabiz.com
|
AbGenomics raises $9.6 mn for advancing its therapeutic antibodies for …
pharmabiz.com The company will use the raised amount to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics’ lead drug candidate AbGn-168H, a first-in-class humanized monoclonal antibody that specifically depletes chronic … |
